HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes

HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes

Background: Data on patient outcomes with human epidermal growth factor receptor 2 (HER2)-directed therapy after detection of ERBB2 amplification (ERBB2 amp) by circulating tumor DNA (ctDNA) are lacking in advanced gastroesophageal adenocarcinoma (aGEA). We report real-world outcomes in aGEA patient...

Full description

Bibliographic Details
Main Authors: S. Chakrabarti, L. Bucheit, J. Saha, K. Clemens, R. Barnett, N. Zhang, A. Mahipal
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:ESMO Gastrointestinal Oncology
Subjects:
ERBB2
gastroesophageal
ctDNA
liquid biopsy
real-world evidence (RWE)
Online Access:http://www.sciencedirect.com/science/article/pii/S2949819824000177

Internet

http://www.sciencedirect.com/science/article/pii/S2949819824000177

Similar Items